NOX Share Price Performance
Recent NOX News & Updates
No updates
Noxopharm Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.0079
- Gross Margin
- -29.44%
- Net Profit Margin
- -98.79%
- Debt/Equity Ratio
- 0%
Noxopharm Limited Competitors
About NOX
- Founded
- 2015
- Employees
- n/a
- CEO
- WebsiteView website
Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions. The company also develops orphan drug designations to treat less common disease; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. Noxopharm Limited was incorporated in 2015 and is based in Glenhaven, Australia.
Australian Market Performance
- 7 Days: -0.2%
- 3 Months: 5.6%
- 1 Year: 8.6%
- Year to Date: 5.1%
Over the last 7 days, the market has remained flat, although notably the Materials sector declined by 4.2%. Meanwhile, the market is actually up 8.6% over the past year. Earnings are forecast to grow by 11% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading